The biotech that raised $1.8 billion promising to sell cancer drugs at 90% off list price — then failed its clinical trials, collapsed its SPAC valuation from $3.4B to near zero, and merged away
Years-long decline before final shutdown · Fatal mistake: Drug candidates failed Phase 2 and Phase 3 clinical endpoints — the entire pricing disruption strategy is inoperable without drugs that work
Evaluating only EQRx’s profile at its peak — without knowing the outcome — the model ranked Unit economics as the #1 likely cause. Documented cause: Founder chaos.
Key Events Timeline
FUNDING
EQRx raises $500M Series A at $3.4B valuation for a pre-revenue biotech; a16z, ARCH Venture Partners lead; mission framing attracts widespread press coverage and policy attention.
FUNDING
EQRx completes SPAC merger with CMLS Holdings at ~$3.4B implied valuation; lists on NASDAQ; executive team announces accelerated clinical trial programme.
DOWN ROUND
Multiple drug candidates fail primary clinical endpoints; pipeline reassessed as insufficient to support current valuation; stock falls from $10 SPAC price to under $1.
ACQUISITION ATTEMPT
EQRx announces merger with Revolution Medicines at consideration effectively wiping out EQRx shareholders vs SPAC entry price; drug pricing disruption mission ends; remaining pipeline absorbed.
Full Analysis
Free · no account needed
Documented cause
EQRx was founded in 2019 by Alexis Borisy — a prolific biotech entrepreneur and investor — and Sandra Horning, the former Chief Medical Officer of Genentech, with a genuinely ambitious mission: develop or license lower-cost versions of expensive cancer drugs and bring them to market at prices 80-90% below standard US list prices. The premise challenged the fundamental assumption of the biopharmaceutical industry: that drug development costs justify multi-hundred-thousand-dollar annual price tags. EQRx raised $1.8 billion from a16z, ARCH Venture Partners, Casdin Capital, and GV across multiple rounds, attracting investors energised by the pricing reform narrative. In December 2022, EQRx completed a SPAC merger with CMLS Holdings at an implied valuation of approximately $3.4 billion, listing on NASDAQ. The strategy required building a clinical pipeline of lower-cost drug candidates, either through independent development or in-licensing from lower-cost manufacturers. Both paths proved more difficult than projected: drugs developed internally failed to meet clinical endpoints in Phase 2 and Phase 3 trials, while in-licensed candidates faced market access obstacles from payers and hospital formularies who were skeptical of unproven Chinese-manufactured generics. Revenue did not materialize at the scale needed to justify the capital structure. By mid-2023, EQRx shares had fallen from $10 at SPAC merger to under $1. In October 2023, EQRx announced a merger with Revolution Medicines — a legitimate oncology company but one with a different mission — at a consideration effectively wiping out EQRx shareholders relative to their SPAC entry price. The ambitious drug pricing disruption narrative ended as a cautionary tale about the gap between reformist mission and clinical execution.
Lesson
“A reformist mission in healthcare is not a substitute for clinical execution. EQRx correctly identified that drug prices were broken; it incorrectly assumed that identifying the problem was the hardest part. Developing drugs that pass Phase 3 trials at any price point is the actual constraint — the pricing strategy is irrelevant if the clinical program fails. Raising $1.8B buys you the right to discover this lesson at maximum expense.”
Failure anatomy
Collapse type
Slow Death
🐌 LOW
Hype cycle
drug pricing reform / spac biotech wave
Moat type
Mission Brand + Reformist Narrative
Fatal mistake
Drug candidates failed Phase 2 and Phase 3 clinical endpoints — the entire pricing disruption strategy is inoperable without drugs that work